Christopher H. van Dyck (born 25 August 1955), is the Founder and Director of the Alzheimer's Disease Research Unit (ADRU) at Yale University School of Medicine, where he is Professor of Psychiatry, Neurology and Neuroscience.
Studies of this ligand in early Alzheimer's Disease patients have shown a loss of synapses from the perforant path, the connections between the entorhinal cortex and hippocampal formation needed for memory consolidation.
They have contributed to the successful development of memantine now in use for the treatment of mid-late stage Alzheimer's Disease,[6] and assess potential new therapeutic strategies, e.g. antibodies that reduce amyloid pathology such as Crenezumab,[7] and based on the work of Dr. Stephen Strittmatter, an inhibitor of fyn.
[8] van Dyck is the lead author on the New England Journal of Medicine report on lecanemab, the first treatment to significantly slow the course of Alzheimer's disease.
Dr. van Dyck is the Chair of the Medical and Scientific Advisory Council of the Connecticut chapter of the Alzheimer's Association.